Presentation Stuff Flashcards Preview

PHAR 409 > Presentation Stuff > Flashcards

Flashcards in Presentation Stuff Deck (60)
Loading flashcards...
1

Prolia: Indication

Osteoporosis in men

2

Prolia: MOA

RANK ligand (RANKL) inhibitor > prevents formation of osteoclasts

3

Prolia: dosing freq

one injection q6 mths

4

Prolia: route

SC

5

Prolia: Place in tx

EDS: used if failed bisphosphonates

6

Prolia: AEs

nasopharyngitis, back pain (bone-related), arthralgia (bone-related)

HTN (less common)

7

Prolia: cost

More than bisphosphonates

8

Insulin glargine: indication

T1/T2DM

9

Insulin glargine: MOA

mimics body's basal insulin release > stimulates glucose uptake and inhibits hepatic glucose production

10

Insulin glargine: dosing freq

qd @ same time

11

Insulin glargine: route

SC

12

Insulin glargine: AEs

nasopharyngitis, URTI, diarrhea, hypoglycemia (less common w/ LA insulins)

13

Insulin glargine: cost

cheaper than Lantus (and more effective than it fyi)

14

Praluent: indication

for familial hypercholesterolemia

15

Praluent: MOA

binds to PCSK9 enzymes > reduces degradation of LDL receptors > increased LDL binding and removal

16

Praluent: route

SC

17

Praluent: place in tx

adjunct to high-dose statins

18

Actemra: indication

Rheumatoid arthritis

19

Actemra: MOA

binds IL-6 receptors > inhibits their signalling > reduces inflammation in joints

20

Actemra: route

IV/SC

21

Actemra: place in tx

EDS:
1. mod-sev RA as monotx or in combo w/ methotrexate or other DMARDs
2. failed DMARDs (dz modifying antirheumatic drugs)

22

Infliximab: indication

UC

23

Infliximab: MOA

binds to TNF-a > inhibits its activity > autoimmune response and inflammation are mitigated

24

Infliximab: route

IV

25

Infliximab: place in tx

reserved for pts who've exhaused first-line tx's for their UC

26

Benlysta: indication

systemic lupus erythematosus (i.e. lupus)

27

Benlysta: MOA

binds to B cell stimulator > B cell death > unable to differentiate into plasma cells > reduced Ig production > reduced autoimmune response

28

Benlysta: route

IV/SC

29

Interferon beta-1A: indication

MS (relapsing-remitting MS, high risk of progression to MS)

30

Interferon beta-1A: MOA

blocks action + entry of immune cells > reduced damage to myelin